PMID- 33578850
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 2
DP  - 2021 Feb 10
TI  - Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand 
      Multispecific Viral and Tumor Antigen-Specific T-Cells.
LID - 10.3390/vaccines9020141 [doi]
LID - 141
AB  - Because dendritic cells are crucial to prime and expand antigen-specific CD8(+) 
      T-cells, several strategies are designed to use them in therapeutic vaccines 
      against infectious diseases or cancer. In this context, off-the-shelf allogeneic 
      dendritic cell-based platforms are more attractive than individualized autologous 
      vaccines tailored to each patient. In the present study, a unique dendritic cell 
      line (PDC*line) platform of plasmacytoid origin, already used to prime and expand 
      antitumor immunity in melanoma patients, was improved thanks to retroviral 
      engineering. We demonstrated that the clinical-grade PDC*line, transduced with 
      genes encoding viral or tumoral whole proteins, efficiently processed and stably 
      presented the transduced antigens in different human leukocyte antigen (HLA) 
      class I contexts. Moreover, the use of polyepitope constructs allowed the 
      presentation of immunogenic peptides and the expansion of specific cytotoxic 
      effectors. We also demonstrated that the addition of the Lysosome-associated 
      membrane protein-1 (LAMP-1) sequence greatly improved the presentation of some 
      peptides. Lastly, thanks to transduction of new HLA molecules, the PDC platform 
      can benefit many patients through the easy addition of matched HLA-I molecules. 
      The demonstration of the effective retroviral transduction of PDC*line cells 
      strengthens and broadens the scope of the PDC*line platform, which can be used in 
      adoptive or active immunotherapy for the treatment of infectious diseases or 
      cancer.
FAU - Lenogue, Kevin
AU  - Lenogue K
AD  - Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced 
      Biosciences, INSERM U1209, CNRS UMR 5309, Universite Grenoble Alpes, 38700 La 
      Tronche, France.
AD  - PDC*line Pharma, 38701 Grenoble, France.
AD  - Research and Development laboratory, Etablissement Francais du Sang 
      Auvergne-Rhone-Alpes, 38701 Grenoble, France.
FAU - Walencik, Alexandre
AU  - Walencik A
AD  - Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced 
      Biosciences, INSERM U1209, CNRS UMR 5309, Universite Grenoble Alpes, 38700 La 
      Tronche, France.
AD  - HLA Laboratory, Etablissement Francais du Sang Centre-Pays de la Loire, 44011 
      Nantes, France.
FAU - Laulagnier, Karine
AU  - Laulagnier K
AD  - PDC*line Pharma, 38701 Grenoble, France.
FAU - Molens, Jean-Paul
AU  - Molens JP
AD  - Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced 
      Biosciences, INSERM U1209, CNRS UMR 5309, Universite Grenoble Alpes, 38700 La 
      Tronche, France.
AD  - Research and Development laboratory, Etablissement Francais du Sang 
      Auvergne-Rhone-Alpes, 38701 Grenoble, France.
FAU - Benlalam, Houssem
AU  - Benlalam H
AD  - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, 44011 Nantes, France.
FAU - Dreno, Brigitte
AU  - Dreno B
AD  - Onco-Dermatology Department, CHU Nantes, CIC 1413, CRCINA, Universite de Nantes, 
      44093 Nantes, France.
FAU - Coulie, Pierre
AU  - Coulie P
AD  - De Duve Institute, Universite Catholique de Louvain, B-1200 Brussels, Belgium.
FAU - Pule, Martin
AU  - Pule M
AD  - Cancer Institute, University College London, London WC1E 6BT, UK.
FAU - Chaperot, Laurence
AU  - Chaperot L
AUID- ORCID: 0000-0002-1479-9410
AD  - Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced 
      Biosciences, INSERM U1209, CNRS UMR 5309, Universite Grenoble Alpes, 38700 La 
      Tronche, France.
AD  - Research and Development laboratory, Etablissement Francais du Sang 
      Auvergne-Rhone-Alpes, 38701 Grenoble, France.
FAU - Plumas, Joel
AU  - Plumas J
AUID- ORCID: 0000-0002-5005-4301
AD  - Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced 
      Biosciences, INSERM U1209, CNRS UMR 5309, Universite Grenoble Alpes, 38700 La 
      Tronche, France.
AD  - PDC*line Pharma, 38701 Grenoble, France.
AD  - Research and Development laboratory, Etablissement Francais du Sang 
      Auvergne-Rhone-Alpes, 38701 Grenoble, France.
AD  - Cancer Institute, University College London, London WC1E 6BT, UK.
LA  - eng
GR  - FP7-PEOPLE-2009-IEF Proposal n degrees  251033 - Acronym: PDC Therapy/FP7 People: 
      Marie-Curie Actions/
PT  - Journal Article
DEP - 20210210
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC7916617
OTO - NOTNLM
OT  - cancer diseases
OT  - immunotherapy
OT  - infectious diseases
OT  - plasmacytoid dendritic cells
OT  - vaccination
COIS- Joel Plumas has been the Chief Scientific Officer of PDC*line Pharma since 2014. 
      Pierre Coulie is a member of the Scientific Advisory Board of PDC*line Pharma.
EDAT- 2021/02/14 06:00
MHDA- 2021/02/14 06:01
PMCR- 2021/02/10
CRDT- 2021/02/13 01:01
PHST- 2021/01/07 00:00 [received]
PHST- 2021/02/03 00:00 [revised]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/02/13 01:01 [entrez]
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/02/14 06:01 [medline]
PHST- 2021/02/10 00:00 [pmc-release]
AID - vaccines9020141 [pii]
AID - vaccines-09-00141 [pii]
AID - 10.3390/vaccines9020141 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Feb 10;9(2):141. doi: 10.3390/vaccines9020141.